Tenderwize
Zurück zur Suche

Open house rebate agreements Abatacept, ATC L04AA24

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline May 03, 2028 · 614 days left·Open·Supplies·Framework
Registrieren zum SpeichernOpen documents
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Abatacept, ATC L04AA24

50/100

Opportunity Score

Needs reviewLow complexity
SuppliesFrameworkOpen
Warum diese Bewertung?

Chance

50 / 100

Komplexität

30 / 100

Risikofaktoren

No estimated value or volume is provided. The actual business volume under the agreement is unknown and may be very low.

The agreement automatically becomes void if a nationwide or regional rebate contract for the same substance is conclude...

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Jun 2028
  • Non-exclusive rebate agreements for Abatacept (ATC L04AA24) as per § 130a Abs. 8 SGB V
  • Standardized contract terms, not individually negotiable
Vollständige Zusammenfassung anzeigen

Open-house model for non-exclusive rebate agreements on Abatacept (ATC L04AA24) by AOK Bayern. Any eligible pharmaceutical company can conclude a standard contract without competitive selection. Contract runs from 01 July 2026 to 30 June 2028. Rolling entry with monthly cutoffs; final deadline for contract conclusion is 03 May 2028. No estimated value or volume is provided.

Risiken

No estimated value or volume is provided. The actual business volume under the agreement is unknown and may be very low.

The agreement automatically becomes void if a nationwide or regional rebate contract for the same substance is conclude...

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Technical

  • Contract and annex must be signed by an authorized representative (proof of authority required via commercial register extract or power of attorney)

Eligibility

  • Only pharmaceutical companies are eligible to participate

Administrative

  • Must submit a signed declaration of reliability

Auftraggeber

Ort

München, DEU

Website

www.aok.de

Auftraggeberprofil

Profil öffnen

Kennung

DE811695320

Tätigkeit

Health

Lose (1)

LOT-0001

Open house rebate agreements Abatacept, ATC L04AA24

Non-exclusive rebate agreement for the active substance Abatacept. The contract is a standard, non-negotiable agreement offered to all interested pharmaceutical companies meeting eligibility criteria. The contract can be terminated with one month's notice. It automatically becomes void if a nationwide or region-specific rebate contract for the same substance is concluded via an open procedure.

SuppliesFrameworkEU fundedElectronic submission

Ort

DE212, Germany

Dauer

Jun 2026 - Jun 2028

Kategorie

Pharmaceutical products

Frist

Deadline May 03, 2028

Vergabedetails

Veröffentlichungsdatum
17 May 2026
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
336029-2026

Dokumente (2)

Vergabedokument 1Einreichungsportal 1

Ähnliche Ausschreibungen

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30